Free Trial

Eterna Therapeutics (ERNA) Competitors

Eterna Therapeutics logo
$0.47 +0.05 (+11.06%)
As of 01/21/2025 04:00 PM Eastern

ERNA vs. KZIA, GRI, ADIL, ALZN, TRIB, GNPX, EVOK, AEZS, VINC, and EDSA

Should you be buying Eterna Therapeutics stock or one of its competitors? The main competitors of Eterna Therapeutics include Kazia Therapeutics (KZIA), GRI Bio (GRI), Adial Pharmaceuticals (ADIL), Alzamend Neuro (ALZN), Trinity Biotech (TRIB), Genprex (GNPX), Evoke Pharma (EVOK), Aeterna Zentaris (AEZS), Vincerx Pharma (VINC), and Edesa Biotech (EDSA). These companies are all part of the "pharmaceutical products" industry.

Eterna Therapeutics vs.

Kazia Therapeutics (NASDAQ:KZIA) and Eterna Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, community ranking, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Kazia Therapeutics currently has a consensus price target of $20.00, suggesting a potential upside of 1,288.89%. Given Kazia Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Kazia Therapeutics is more favorable than Eterna Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kazia Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Eterna Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

30.9% of Kazia Therapeutics shares are held by institutional investors. Comparatively, 70.6% of Eterna Therapeutics shares are held by institutional investors. 1.0% of Kazia Therapeutics shares are held by insiders. Comparatively, 4.5% of Eterna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Kazia Therapeutics has a net margin of 0.00% compared to Eterna Therapeutics' net margin of -7,513.88%.

Company Net Margins Return on Equity Return on Assets
Kazia TherapeuticsN/A N/A N/A
Eterna Therapeutics -7,513.88%N/A -117.48%

Kazia Therapeutics has a beta of 2.12, indicating that its stock price is 112% more volatile than the S&P 500. Comparatively, Eterna Therapeutics has a beta of 4.29, indicating that its stock price is 329% more volatile than the S&P 500.

Kazia Therapeutics has higher revenue and earnings than Eterna Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kazia Therapeutics$2.31M2.72-$17.56MN/AN/A
Eterna Therapeutics$70K36.24-$21.67M-$8.31-0.06

In the previous week, Kazia Therapeutics' average media sentiment score of 0.00 beat Eterna Therapeutics' score of -0.26 indicating that Kazia Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Kazia Therapeutics Neutral
Eterna Therapeutics Neutral

Kazia Therapeutics received 79 more outperform votes than Eterna Therapeutics when rated by MarketBeat users.

CompanyUnderperformOutperform
Kazia TherapeuticsOutperform Votes
79
52.67%
Underperform Votes
71
47.33%
Eterna TherapeuticsN/AN/A

Summary

Kazia Therapeutics beats Eterna Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Eterna Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ERNA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ERNA vs. The Competition

MetricEterna TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2.54M$6.58B$5.39B$9.13B
Dividend YieldN/A2.96%5.37%4.00%
P/E Ratio-0.0610.0188.8317.53
Price / Sales36.24337.621,282.53134.37
Price / CashN/A22.6336.6032.90
Price / Book1.145.084.964.69
Net Income-$21.67M$154.90M$117.89M$224.57M
7 Day Performance2.38%2.59%2.75%3.33%
1 Month Performance87.49%1.52%3.63%5.33%
1 Year Performance-66.50%5.49%27.27%22.97%

Eterna Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ERNA
Eterna Therapeutics
1.0682 of 5 stars
$0.47
+11.1%
N/A-66.5%$2.54M$70,000.00-0.0610Gap Up
KZIA
Kazia Therapeutics
3.1871 of 5 stars
$1.51
-4.4%
$20.00
+1,224.5%
-58.9%$6.58M$2.31M0.0012Gap Up
GRI
GRI Bio
2.7518 of 5 stars
$0.73
-4.3%
$11.50
+1,475.3%
-97.2%$6.52MN/A-0.781
ADIL
Adial Pharmaceuticals
3.1295 of 5 stars
$1.01
-1.0%
$8.00
+692.1%
-23.7%$6.47MN/A0.0020Positive News
Gap Down
ALZN
Alzamend Neuro
2.3283 of 5 stars
$1.15
+1.8%
$32.00
+2,682.6%
-86.6%$6.25MN/A0.004Positive News
TRIB
Trinity Biotech
1.507 of 5 stars
$0.82
-2.0%
N/A-63.0%$6.25M$59.13M-0.36480Positive News
GNPX
Genprex
4.24 of 5 stars
$0.73
-6.4%
$10.00
+1,269.7%
-91.7%$6.21MN/A0.0020Positive News
EVOK
Evoke Pharma
0.812 of 5 stars
$4.17
-0.7%
N/A-51.7%$6.20M$8.62M-0.384Positive News
AEZS
Aeterna Zentaris
N/A$3.40
+5.7%
N/A-62.5%$6.10M$2.37M-0.2320Analyst Forecast
VINC
Vincerx Pharma
2.5157 of 5 stars
$0.18
-5.9%
$2.00
+1,017.9%
-86.2%$6.02MN/A-0.1760Gap Up
EDSA
Edesa Biotech
3.3091 of 5 stars
$1.73
-2.5%
$21.00
+1,113.9%
-60.7%$6MN/A-0.9020Positive News

Related Companies and Tools


This page (NASDAQ:ERNA) was last updated on 1/22/2025 by MarketBeat.com Staff
From Our Partners